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Introduction
• Multiple myeloma (MM) is a malignancy of plasma cells that accounts for
approximately 1 to 2 percent of all cancers and about 17% of all
hematologic malignancies.
• Plasma cells normally produce antibodies and provide a defense
mechanism for the body to fight infections.
• Antibodies typically consist of two heavy chains (IgG, IgA, IgM, IgD and
IgE) and two light chains (kappa and lambda).
• Most cases of MM have malignant plasma cells producing monoclonal
(M) proteins, most common being IgG about 52% of the time (1).
• Only about 2% of these myeloma cases were also found to secrete more
than one paraprotein and classified as biclonal/biphenotypic plasma cell
myeloma (2).
• Here we report a case of a woman who presented with lower back pain
that was found to have biphenotypic multiple myeloma with a
coexpression of kappa and lambda light chains.

Case Presentation
• 52-year-old African American female was admitted with a chief complaint
of lower back pain for a 3-4 months duration.
• PMH: hypertension, peptic ulcer disease and gastroesophageal reflux
disease
• Labs were significant for elevated serum creatinine of 6.13 and serum
calcium of 12.5, hemoglobin of 8.4.
• Renal ultrasound showed no hydronephrosis or renal calculi, increased
bilateral cortical echogenicity, indicative of some degree of underlying
chronic kidney disease.
• SPEP showed positive free lambda (23993), positive free kappa light
chain (43.2) normal IgG and IgA ratio, low IgM (25).
• Urinalysis was significant of 100+ protein and urine protein to creatinine
ratio consistent with 11.97 grams
• Bone Survey showed heterogenous appearance of the right humerus
with scattered ill-defined lytic lesions. Possible ill-defined lytic lesions are
seen at the proximal left tibia. There was a lytic lesion at the proximal left
radius.
• Treated with dexamethasone for multiple myeloma and pamidronic acid
for hypercalcemia with a resolution of serum calcium level to 8.5mg/dL.
• Patient also required hemodialysis for her acute renal failure.
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Discussion
• In older patients presenting with lower back pain and acute renal failure,
the diagnosis of multiple myeloma should be on the differential
• MM the leading cause of malignancy induced ESRD requiring dialysis.
• The kidneys metabolizes light chain proteins but Ig and heavy chains do
not pass through the glomerular filtration barriers.
• Light chains that are filtered are reabsorbed by proximal tubular cells and
catabolized by lysozymal enzymes, normally this process is very efficient.
• When the burden of light chains exceeds the absorption capacity of the
tubules, light chains spill into the urine (3).
• Free light chains enter proximal tubule cells and trigger apoptosis and
inflammation (4).
• Free light chains bind to Tamm-Horsfall protein to form casts which result
in tubular atrophy, interstitial inflammation and fibrosis leading to renal
failure

Treatment Options
• Early diagnosis and initiation of therapy is the best treatment
• MM patients requiring dialysis have a higher mortality than other causes
of ESRD with a greater than 85% mortality within 2 years (5).
• Pharmacologic Therapy-Bortezomib-based therapy, especially triple drug
therapy (thalidomide, dexamethasone and bortezomib) has improved
survival of patients with mild to moderately reduced kidney function and
those requiring dialysis.
• Plasmapheresis-removing light chains from plasma leading to less being
filtered by the kidney and causing less damage. Studies have shown
mixed results with no clear evidence of mortality benefit.
• Stem cell transplantation (SCT)-potentially curative for a small number of
patients. Interesting renal failure may prevent patient’s them from
qualifying for SCT, one of the disease’s most effective treatments (6).
• Kidney transplant-clear curative option for patients with MM and ESRD
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